<div id="readability-page-1">US stock futures are slightly lower this Wednesday morning, but several individual stocks are making sharp moves on index changes, FDA approvals, earnings, and corporate actions. Here are the stocks investors are watching today: UiPath (PATH) Surged after S&amp;P Dow Jones Indices announced UiPath will join the S&amp;P MidCap 400, replacing Synovus Financial, effective January 2, 2026. Shares jumped 6.8 percent to $17.05 in after-hours trading. Agios Pharmaceuticals (AGIO) Announced FDA approval of Mitapivat (EcVSmi) to treat anemia in adults with alpha or beta thalassemia. Despite the approval, shares slipped 1.4 percent to $24.59. Fight BioPharma (FIGHT) Announced a 1-for-3000 reverse stock split, sending shares down 28.8 percent to $0.17 after hours. Cush Pharmaceuticals (CUSH) Delivered better-than-expected Q4 results, posting a $0.11 loss per share versus estimates of a $0.43 loss. Shares surged 22.1 percent to $1.27 after hours. Ramaco Resources (METC) Jumped 7.1 percent to $18.09 after announcing a $100 million share buyback program.</div>

Agios制藥

METC

PATH

<p>美國股指期貨略微下跌，但個股卻出現劇烈波動。UiPath 在加入標準普爾中型股 400 指數後上漲 6.8%。儘管 Agios Pharmaceuticals 獲得了 FDA 對 Mitapivat 的批准，但股價仍下跌 1.4%。Fight BioPharma 在進行反向股票拆分後下跌 28.8%。Cush Pharmaceuticals 因第四季度業績好於預期上漲 22.1%。Ramaco Resources 在宣佈 1 億美元的股票回購計劃後上漲 7.1%</p>

今天需要關注的五隻股票 | 股市在聖誕前夕開放